Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. - Wikidata - awgldk - TriplyDB

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

http://www.wikidata.org/entity/Q36917485

about

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies The functional cancer map: a systems-level synopsis of genetic deregulation in cancer Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo Cancer module genes ranking using kernelized score functions An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer New strategies in hepatocellular carcinoma: genomic prognostic markers.Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro.Exploring genomic profiles of hepatocellular carcinoma.Prognostic value of DNA repair based stratification of hepatocellular carcinoma Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.Targeted therapies for hepatocellular carcinoma.Molecular targeted therapies in hepatocellular carcinoma MicroRNA involvement in hepatocellular carcinoma.Novel inhibitors in development for hepatocellular carcinoma.Developing better treatments in hepatocellular carcinoma.MicroRNA profiling in cancer.Blood oxygen level-dependent liver MRI: can it predict microvascular invasion in HCC?Treatment of hepatocellular carcinoma: present and future.Systemic therapies in hepatocellular carcinoma: present and future.Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro.Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling.Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.Drug response prediction model using a hierarchical structural component modeling method

P2860

Q28383646-168245B3-9C00-4806-A75C-596E7B0AFD11 Q33895113-AE723897-14AB-4CC7-864D-CC4955E52E73 Q33947216-60B9640B-E25E-41A7-8F84-A3E5712D143C Q34268708-0B41D217-A9CD-456A-9AC4-4724CF3FB3D1 Q34456928-C486001E-F728-4038-A102-F7DAA3EB83C0 Q34802527-1EA7FD4F-7E2F-4455-A0D1-DCCFFD068CBD Q36090222-1247704F-4549-4786-8F17-2D30FED1B5DD Q36226728-CC63A22F-F766-4885-A940-3D8C96A2512F Q36393332-C8D66B20-79F4-42B4-95ED-A06B2D6DAFA7 Q36903275-39083BA2-8148-4294-860E-01DD58E29456 Q36914691-CCA409A5-0AA8-4F47-86D2-417B6BA31EE9 Q36928888-1636801F-BDD8-4045-95F4-B24D05A3D0ED Q37003665-DFEDD039-6024-4545-92E0-D2E99D3982CE Q37361575-0017B821-05B8-43E8-A803-432413E96A15 Q37725994-0AF56712-5864-4CE0-B0F3-A73F338C2130 Q37798817-90F42FA3-1DE3-41EB-AC57-1A9050D3474E Q37869934-A942AE01-DFDB-4B7B-A743-7C901985D66B Q38057714-226D8DD7-F596-4CD2-AC3B-23C836B22547 Q38096477-132675C0-2165-43F5-85F0-1D9C5BAB70D6 Q38150875-89FAF81F-82C0-408C-8AFA-F5C2C3F10ABE Q39192357-A94E3CF9-136E-47EF-86EA-E51535C905C0 Q39466467-BDD5580E-A4CA-42A5-A57D-B53039947760 Q42064207-CCA677A4-2E08-4BCC-BE69-689150B6135A Q42067728-B7E6BDB2-1ABC-4B61-9ECF-AF6A95C0974F Q42341423-6327B313-BF40-4C91-9E25-C83A29C91078 Q53228628-8A6C09A3-1EF6-4900-9354-D1FEE25E0162 Q58785493-53C4E3EE-BD5A-4D06-9420-EB60A7A43AFC

P2860

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

http://www.wikidata.org/entity/Q36917485

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Linking molecular classificati ...... d medicine: preliminary steps.

@en

type

label

Linking molecular classificati ...... d medicine: preliminary steps.

@en

prefLabel

Linking molecular classificati ...... d medicine: preliminary steps.

@en

P1433

Q36917485-6AFB826B-AACA-4F31-8730-3BA9232B0415

P1476

Q36917485-40ABEE3D-8B13-4510-A52C-285D21AC8E48

P2093

Q36917485-5C761CF5-8580-454E-9A52-3F444D0973AA

P2860

Q36917485-0078C802-D631-46E7-B41F-DB0193F8893A

Q36917485-01FDECC2-F718-46F3-B795-CAE806BB53B0

Q36917485-03B60482-C460-4F1B-8F60-94AB23E77516

Q36917485-05F2B8FF-1730-48E9-9FF5-F836EB5FC3DF

Q36917485-08761A9A-D248-4D73-A518-6308AFB990E2

Q36917485-11BA776C-1487-4CE3-9524-3563C9D2761A

Q36917485-2646560B-E6C0-47F7-A35A-6FDBD01FD0B3

Q36917485-2889C49C-2E42-4674-9DF9-AAD778A8CE69

Q36917485-2BAFD24C-9DBD-4C4D-9EC0-E6050AE3AB2C

Q36917485-2DA4B884-8D93-4DF3-8078-14021C33DF47

P304

Q36917485-63F5ACB6-2E58-4DC0-9AEE-BC81F637217E

P31

Q36917485-32588E81-E8A3-40EA-9C1C-8275A97DB460

P356

Q36917485-71B8430F-0DBB-4098-A1CB-B8168DCA4FC1

P433

Q36917485-4811E924-B1A5-416E-A472-7BE3B0B69B92

P478

Q36917485-6368F592-9041-49D8-8A0A-E816425A36EC

P50

Q36917485-5510F1C7-AD33-4EF4-B6A7-240BDC89D6BA

Q36917485-BD41D42B-991D-4281-BB42-D89C7675ADDE

P577

Q36917485-0290006C-E330-470B-B95D-50E1DC157609

P5875

Q36917485-2C678D4E-D274-4221-B4FE-7F4038F57693

P698

Q36917485-26B3DBB7-6BA3-4B00-879E-19B6D1C27D67

P932

Q36917485-15508BAE-6310-471D-8A33-B668CB2DB557

P356

CCO.0B013E328302C9E9

P1433

Current Opinion in Oncology

P1476

Linking molecular classificati ...... ed medicine: preliminary steps

@en

P2093

Sara Toffanin

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Cluster analysis and display of genome-wide expression patterns

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

A gene-expression signature as a predictor of survival in breast cancer

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

APC mutations occur early during colorectal tumorigenesis

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

P304

444-453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CCO.0B013E328302C9E9

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Josep M. Llovet

Augusto Villanueva

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51401630

http://www.w3.org/2001/XMLSchema#string

P698

18525342

http://www.w3.org/2001/XMLSchema#string

P932

3678124

http://www.w3.org/2001/XMLSchema#string